» Articles » PMID: 24722063

Clinical, Morphologic, Phenotypic, and Genetic Evidence of Cyclin D1-positive Diffuse Large B-cell Lymphomas with CYCLIN D1 Gene Rearrangements

Overview
Date 2014 Apr 12
PMID 24722063
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Overexpression of cyclin D1 in diffuse large B-cell lymphomas (DLBCLs) is observable in about 5% of cases and is linked to gains of additional CYCLIN D1 gene copies or deregulation at the mRNA level. All cyclin D1-positive DLBCL cases reported so far lack the canonical t(11;14)(q13;q32) translocation that is a genetic hallmark and the primary cause of cyclin D1 overexpression in mantle cell lymphoma (MCL). Using standard histologic and genetic techniques, complemented with genome-wide aberration analysis by array comparative genomic hybridization, we characterized 2 exceptional cases of blastoid B-cell lymphomas with cyclin D1 overexpression, both bearing genetic rearrangements in the CYCLIN D1 gene locus. One of them had a t(11;14)(q13;q32) translocation and featured morphology, immunophenotype, and genetic copy number aberrations typical of DLBCL. The second case had a complex t(4;11;14) translocation, but the other features were intermediate between DLBCL and MCL and did not allow unambiguous classification in any of the current diagnostic lymphoma categories. On the basis of these findings, we conclude that detection of t(11;14) should not preclude a diagnosis of cyclin D1-positive DLBCL when all other parameters are in agreement with such a diagnosis. Moreover, a yet unacknowledged diagnostic "gray zone" may exist between DLBCL and MCL.

Citing Articles

Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.

Ozogul E, Montaner A, Pol M, Frigola G, Balague O, Syrykh C Blood Cancer J. 2024; 14(1):166.

PMID: 39313500 PMC: 11420347. DOI: 10.1038/s41408-024-01146-z.


Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements.

Monika F, Sabri A, Cantu D, Vail E, Siref A J Hematop. 2024; 17(3):155-161.

PMID: 38914869 PMC: 11324669. DOI: 10.1007/s12308-024-00593-8.


Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma.

Chuang W, Chang H, Shih L, Lin T, Yeh C, Ueng S Virchows Arch. 2024; 485(2):323-334.

PMID: 38733379 DOI: 10.1007/s00428-024-03813-9.


Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.

Quintanilla-Martinez L, Laurent C, Soma L, Ng S, Climent F, Ondrejka S Virchows Arch. 2023; 483(3):281-298.

PMID: 37555980 PMC: 10541818. DOI: 10.1007/s00428-023-03590-x.


Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.

Rodriguez-Pinilla S, Dojcinov S, Dotlic S, Gibson S, Hartmann S, Klimkowska M Virchows Arch. 2023; 484(1):15-29.

PMID: 37530792 PMC: 10791773. DOI: 10.1007/s00428-023-03579-6.